Spectrum has a broad and diversified portfolio of proprietary drugs in various stages of development in the fields of oncology and urology.
Zevalin® (ibritumomab tiuxetan), an FDA-Approved, Proprietary, Biological Drug for Indolent Non-Hodgkin's Lymphoma.
Fusilev® (Levoleucovorin) for injection FDA Approved on March 7, 2008 for High-Dose Methotrexate Rescue Therapy in Osteosarcoma.
Belinostat a novel HDAC inhibitor in late stage clinical development for Peripheral T-cell Lymphoma, and other Solid Tumors (including Carcinoma of Unknown Primary, etc.)
EOquin® (Apaziquone), one of our lead development candidates, is a synthetic bio-reductive prodrug that is being investigated in the treatment of non-invasive bladder cancer, and began two Phase 3 studies in 2007.
Spectrum also has three drugs in the Phase 2 stage of development: Ozarelix, for the treatment of prostate cancer, Ortataxel, for the treatment of taxane-refractory tumors, and Satraplatin, a Phase 2 oral, anti-cancer drug, being investigated for non-small cell lung cancer (NSCLC).
The Company has three drugs in the Phase 1 stage of development: SPI-1620, an adjunct to chemotherapy, Elsamitrucin, which will target advanced solid tumors and Lucanthone, a chemotherapy sensitizer in the treatment of recurrent, malignant brain tumors.
Other drugs in development include RenaZorb™, used in the treatment of hyperphosphotemia in end stage renal disease (ESRD), and SPI-205 for chemotherapy induced neuropathy.
